Table 1.
Characteristics of patients with GT3-HCV infection who received a sofosbuvir containing treatment regime
| Total | SOF + DCV | SOF + DCV + RBV | SOF+ VEL | |
|---|---|---|---|---|
| Sample size | 102 | 57 | 24 | 21 |
| Age | 39.99 (38.22–41.76) | 39.16 (36.83–41.48) | 44.25 (40.8–47.70) | 37.38 (33.10–41.67) |
| Gender (M/F) | 62/40 | 28/29 | 20/4 | 13/8 |
| Route of Infection (Travenous drug abuse/Blood products/Others) |
58/18/26 | 34/7/16 | 10/6/8 | 14/5/2 |
| Cirrhosis(yes/no) | 33/69 | 4/53 | 24/0 | 5/16 |
| Baseline HCV RNA (log10 IU/ml) | 6.23 (6.04–6.43) | 6.26 (5.99–6.54) | 6.33 (5.94–6.73) | 6.04 (5.60–6.48) |
| Baseline ALT (IU/mL) | 95.70 (78.88–112.51) | 102.67 (78.10–127.24) | 112.68 (78.89–146.47) | 57.37 (30.01–84.72) |
| Baseline AST (IU/mL) | 81.96 (72.12–91.80) | 91.33 (77.48–105.19) | 89.86 (71.20–108.52) | 47.50 (31.63–63.36) |
| Baseline TBil (μmol/mL) | 19.95 (18.57–21.32) | 18.91 (17.22–20.59) | 22.01 (18.07–25.94) | 20.42 (18.07–22.77) |
| Baseline PLT (109/L) | 142.94 (129.36–156.52) | 157.65 (139.05–176.25) | 104.96 (79.71–130.21) | 146.43 (117.94–174.91) |
| Baseline FIB-4 | 4.03 (2.99–5.07) | 3.75 (2.27–5.23) | 5.70 (3.81–7.58) | 2.86 (0.52–5.19) |
| Baseline APRI | 2.15 (1.66–2.64) | 2.07 (1.40–2.74) | 3.11 (2.02–4.20) | 1.26 (0.36–2.16) |